Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Invitrogen, a provider of life science technologies, and CytRx's majority-owned subsidiary, RXi Pharmaceuticals have entered into an agreement whereby RXi will exclusively license second generation RNA interference technology from Invitrogen for designated target genes in all human therapeutic categories. Terms of the agreement were not disclosed.
Subscribe to our email newsletter
Invitrogen’s patent applications which are part of this agreement cover stealth and other proprietary technologies related to enhanced configurations of chemically modified double-stranded RNA.
Dr Tod Woolf, president and CEO of RXi, said: “Licensing this broad technology from Invitrogen is part of our strategy to continually enhance our proprietary rxRNA compounds for therapeutic applications.”
Amy Butler, Invitrogen vice president of gene expression profiling, said: “Currently Invitrogen stealth RNAi synthetic duplexes are widely used for RNA interference (RNAi) research across both in vitro and in vivo applications due to their specificity, efficacy and stability. We see the use of our stealth RNAi technology in therapeutics as a natural next step in Invitrogen’s efforts to be at the cutting edge of in vivo gene regulation.”